News | PET Imaging | May 17, 2018

PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Novel PET agent demonstrates value as inflammation biomarker before onset of clinical symptoms

PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

May 17, 2018 — A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and could provide early diagnosis of rheumatoid arthritis, a common autoimmune disease that causes chronic inflammation of joints and can lead to deformity and dysfunction. The study is reported in the featured basic science article in The Journal of Nuclear Medicine’s May issue.

Activated macrophages, white blood cells that help protect the body from harmful bacteria and infected cells, are known to play a pivotal role in rheumatoid arthritis (RA) development. Focusing on the translocator protein (TSPO), which is abundant in activated macrophages, researchers developed fluorine-18 (18F)-FEDAC, a radiolabeled ligand that targets TSPO and binds to it.

“This study is novel because it showed the value of 18F-FEDAC PET as an inflammation biomarker for early detection of rheumatoid arthritis, even before onset of clinical symptoms of joints,” explained Gi Jeong Cheon, M.D., Ph.D., of Seoul National University College of Medicine in Seoul, Korea.

For the study, 18F-FEDAC was tested in a mouse model, using both 18F-FEDAC and 18F-FDG PET imaging. Microscopic examinations of tissue were performed to evaluate macrophages and TSPO expression.

Results showed increased TSPO mRNA and protein expression in activated macrophages, and uptake of 18F-FEDAC in activated macrophages was higher than it was in non-activated cells. In addition, 18F-FEDAC uptake by arthritic joints increased early on (day 23), whereas 18F-FDG uptake did not. However, 18F-FDG uptake by arthritic joints increased at later stages (day 37) to a higher level than 18F-FEDAC uptake.

This early study demonstrates that 18F-FEDAC makes it possible to see active inflammation sites in arthritic joints by targeting TSPO expression in activated macrophages, and it suggests imaging with 18F-FEDAC could be useful when RA is suspected.

Cheon pointed out, “Early treatment can reduce the progression of joint destruction and enhance the effect of disease-modifying antirheumatic drugs or target drugs, because the burden of inflammatory reaction is smaller in the very early phase of RA.” He noted, “We observed that 18F-FEDAC uptake increased in paws of murine RA models in association with TSPO expression of activated macrophages, even before the onset of clinical symptoms of arthritis. 18F-FEDAC can help us to find which patients will actually progress to clinically significant rheumatoid arthritis and need treatment.”

Reflecting on the comparison of 18F-FEDAC PET with 18F-FDG, Cheon stated, “From our data, we found that each tracer may be useful for different information about arthritis — 18F-FEDAC for early detection of subclinical arthritis and 18F-FDG for measuring disease activity of symptomatic arthritis. These findings are expected to contribute to the improvement of personalized therapeutic outcomes by expanding the scope of molecular imaging and nuclear medicine.”

For more information: www.jnm.snmjournals.org

 

Related Content

Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...